ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
78taxs
(36.46)
Submitted: 3/21/2013 6:43:31 PM :
Start Price:
$8.07
ACAD Score:
+63.02
THIS IS GOING TO HELP A LOT OF the sick.
Recs
TMFBiologyFool
(99.10)
Submitted: 11/27/2012 4:18:10 PM :
Start Price:
$4.92
ACAD Score:
-160.67
No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.
Recs
BioPharmacist
(< 20)
Submitted: 11/24/2012 5:00:23 PM :
Start Price:
$2.23
ACAD Score:
+499.53
Good Phase 3 coming
Recs
zzlangerhans
(99.78)
Submitted: 11/23/2012 8:23:49 PM :
Start Price:
$2.17
ACAD Score:
-517.16
I was going to sit this one out, but then I remembered how much I regretted my decision not to red thumb Zalicus ahead of SYNERGY and I decided to go for it. The initial phase III trial of pimavanserin for Parkinson's psychosis failed in 2009 and the simultaneous phase III trial was canceled. I've heard all kinds of reasons why the current phase III trial will be successful (tweaking of clinical sites, entry criteria, study endpoints) but the fact is that most phase III redos fail. Pimavanserin wasn't even Acadia's first major failure - that came in 2008 with the termination of ACP-104 development for schizophrenia.
Even if I'm wrong and the phase III trial is a success, I could still escape this pick with a positive score as the market digests the reality that Acadia will have to run another phase III trial before approval, cash is low, the likelihood of heavy dilution is certain, and pimavanserin will still eventually have to compete with inexpensive generic antipsychotics. Regardless, I have only meaningless CAPS points to lose and all kinds of schadenfreude to gain.
Recs
JorgeAura
(20.32)
Submitted: 11/22/2012 4:32:57 AM :
Start Price:
$2.19
ACAD Score:
-510.38
Were is the insider?
Recs
mekadik
(< 20)
Submitted: 7/22/2012 3:08:08 PM :
Start Price:
$1.50
ACAD Score:
+795.02
very good chance for approval
Recs
SamsaricSufferer
(< 20)
Submitted: 7/4/2012 7:42:42 PM :
Start Price:
$1.87
ACAD Score:
+615.32
New study results to be released soon.
Recs
Recs
SIDRWC
(54.63)
Submitted: 3/30/2012 1:16:24 PM :
Start Price:
$2.13
ACAD Score:
+527.24
Financial backers are extremely strong and are driving this company.
Recs
RBuskey106
(< 20)
Submitted: 3/28/2012 9:22:51 PM :
Start Price:
$2.15
ACAD Score:
+521.68
Chart play. Bottoming here.
Recs
NuclearSteve
(54.96)
Submitted: 12/29/2011 12:49:57 PM :
Start Price:
$1.11
ACAD Score:
+1,109.47
Article from Zacks Biotech Guy - Jason Napodano - trying a strategy where I set 10% stops on all these and let the winners run.
Recs
tcoss
(25.84)
Submitted: 4/28/2011 10:26:03 PM :
Start Price:
$2.98
ACAD Score:
+339.98
I do have my worries about this pick. They do have plenty of cash and a phase III trials in the works. Really this is a bet on the phase III trials.
Recs
drmanand
(63.74)
Submitted: 6/17/2010 8:25:07 PM :
Start Price:
$1.11
ACAD Score:
+1,089.63
Has very important nitch new medications.
a strong buy.
Recs
Ineedmoney101
(64.97)
Submitted: 9/1/2009 4:12:42 PM :
Start Price:
$1.30
ACAD Score:
+909.51
All i can say is wow. Pharmecueticals are supposed to go up during this month, this is a great company with amazing financial statements, it didn't beat the leading parkinsis psychosis drug, big deal, but not this big of a deal. I think i'm gonna need to load up on this one for the rebound.
Recs
BruceInToronto
(83.71)
Submitted: 8/25/2009 4:15:06 PM :
Start Price:
$6.08
ACAD Score:
+63.48
Phase three drug approval coming soon
Recs
tensaibakabon
(< 20)
Submitted: 8/12/2009 2:57:31 AM :
Start Price:
$1.85
ACAD Score:
+581.18
Phase 3 due anytime and as per the CEO will be topline results
Recs
Brian7992
(37.69)
Submitted: 7/29/2009 6:37:35 AM :
Start Price:
$4.24
ACAD Score:
+152.86
End of Phase III Clinical Trials and talk of Buy Out should drive this stock to new highs in the comming weeks! I see a 400 to 800% rise in price.
Recs
Brihally
(90.34)
Submitted: 6/16/2008 7:10:25 PM :
Start Price:
$4.52
ACAD Score:
+178.48
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
Recs
bobby410
(< 20)
Submitted: 12/4/2007 5:35:41 PM :
Start Price:
$11.63
ACAD Score:
+0.18
Have a friend who works there, & things are looking very very good.
Recs
sdpowell
(80.44)
Submitted: 10/29/2007 6:44:10 PM :
Start Price:
$15.16
ACAD Score:
-23.18
huge potential for the drugs they offer, good chance of being acquired by a large company too
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 33 : 1 2 Next »